Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) as a common tumor has a poor prognosis. Recently, a combination of atezolizumab and bevacizumab has been recommended as the preferred regimen for advanced HCC. However, the overall response rate of this therapy is low. There is an urgent need to identify se...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Baifeng, Lin, Haozhong, Lan, Tian, Li, Muqi, Wu, Xiwen, Lin, Shuirong, Song, Zimin, Shen, Shunli, Peng, Baogang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354375/
https://www.ncbi.nlm.nih.gov/pubmed/35932027
http://dx.doi.org/10.1186/s12957-022-02681-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354375/
https://www.ncbi.nlm.nih.gov/pubmed/35932027
http://dx.doi.org/10.1186/s12957-022-02681-4

Ejemplares similares